ASH 2017 – Saturday, December 9

Oral Presentations

8:15AM
Keith McCrae, MD
Building B, Level 3, B304-B305
Long-term maintenance of platelet responses in adult patients with persistent/chronic immune thrombocytopenia treated with fostamatinib: One-year efficacy and safety results

10:15AM
Jaroslaw Maciejewski, MD, PhD
Building C, Level 2, C202-204
Novel therapeutic targets for DNMT3A mutant myeloid neoplasms
Novel genetic events of ARID2 in myelodysplastic syndromes with a distinct morphologic phenotype

10:45PM
Jaroslaw Maciejewski, MD, PhD
Building C, Level 2, C208-C210
Functional and biological implications of CUX1 mutations and deletions in myeloid neoplasms

12PM
Aziz Nazha, MD
Building B, Level 3, B312-B314
Genomic biomarkers to predict response to hypomethylating agents in patients with myelodysplastic syndromes (MDS)

12:45PM
Mikkael Sekeres, MD, MS
Building C, Level 3, Georgia BR 1-3
The Impact of the administration schedule and mutational profile on outcomes of patients with relapsed and refractory acute myeloid leukemia treated with hypomethylating agents: A large, international, multicenter analysis

12:45PM
Aziz Nazha, MD
Building B, Level 3, B312-B314
A personalized prediction model to risk stratify patients with myelodysplastic syndromes (MDS)

1:15PM
Mikkael Sekeres, MD, MS
Building B, Level 3, B312-B314
Promising results of a phase 1/2 clinical trial of ruxolitinib in patients with chronic myelomonocytic leukemia

1:45PM
Anjali Advani, MD
Building C, Level 3, Georgia BR 1-3
A phase 1 trial of MEC (mitoxantrone, etoposide, cytarabine) in combination with ixazomib (MLN9708) for relapsed/ refractory acute myeloid leukemia (AML): Final results

2:15PM
Deepa Jagadeesh, MD
Building A, Level 4, A411-A412
Risk-adapted therapy in adults with burkitt lymphoma: results of NCI 9177, a multicenter prospective phase II study of DA-EPOCH-R

2:30PM
Alok Khorana, MD
Building B, Level 2, B216-B217
Prevalence of venous thromboembolism in cancer patients in the emergency department and associated healthcare resource utilization and expenditure in the United States

4:30PM
Alberto Montero, MD
Building B, Level 3, B302-303
Creation of individualized care plans in high risk oncology patients: A team-based model to decrease unnecessary hospitalizations and ED utilization

5:15PM
Aaron Gerds, MD
Building C, Level 2, C208-C210
Phase I/II trial of glasdegib in heavily pretreated patients with primary or secondary myelofibrosis

Poster Presentations
5:30 to 7:30PM
Building A, Level 1, Hall A2

Betty Hamilton, MD
Evolution in myeloid neoplasm clonal architecture recurrent postallogeneic hematopoietic cell transplantation

Keith McCrae, MD
A descriptive analysis of the demographics and presenting symptoms of patients in the USTMA TTP registry

Alok Khorana, MD
Tissue factor-related biomarkers and prediction of cancer-associated VTE: Correlative analyses of the phacs trial

Aaron Gerds, MD
Examining the treatment patterns and blood counts among patients with polycythemia vera treated with hydroxyurea in the United States: An analysis from the REVEAL study

Mikkael Sekeres, MD, MS
Beliefs and patterns of practice in the management of hyperleukocytosis and leukostasis among health care providers for patients with acute leukemia: A large North American web-based survey

Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for hypomethylating agents (HMAs) use in patients with relapsed and refractory acute myeloid leukemia (RR-AML)

Germline tissues and DNA sequencing analysis methods for optimal somatic variant detection in myelodysplastic syndrome (MDS)

Aziz Nazha, MD
Patterns of genomic associations can define acute myeloid leukemia (AML) phenotype

A personalized prediction model to risk stratify patients with acute myeloid leukemia (AML)

Anjali Advani, MD
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia in the global phase 3 INO-VATE trial: Efficacy and safety by baseline CD22 expression level

Jaroslaw Maciejewski, MD, PhD
High frequency of subclonal myeloid mutations can be found in large granular lymphocyte leukemia

Deepa Jagadeesh, MD
The role of upfront autologous hematopoietic cell transplantation in the treatment of mantle cell lymphoma: A population-based study using the National Cancer Data Base

Safety and preliminary antitumor activity of the anti-PD-1 monoclonal antibody REGN2810 alone or in combination with REGN1979, an anti-CD20 x anti-CD3 bispecific antibody, in patients with B-lymphoid malignancies

Jason Valent, MD
Daratumumab Is safe and highly effective in AL amyloidosis

Initial phase 2 Results of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

Jaroslaw Maciejewski, MD, PhD
TET2 and MSH6: A novel role for MMR in the pathogenesis of myeloid malignancies

Chemotherapy and radiation results in distinct patterns of somatic mutations in subsequent myeloid disease

Germline SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes

Modulation of TET2 activity with ascorbic acid in myeloid neoplasia: Diagnostic and therapeutic implications

Rabi Hanna, MD
Outcomes of immunosuppressive therapy for pediatric aplastic anemia: A North American Pediatric Aplastic Anemia Consortium study
please post as soon as possible – week of 11/27